Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	Conversion Of Convertible Note And Derivative	Common Stock	Common Stock Conversion Of Convertible Note And Derivative	Additional Paid-in Capital	Additional Paid-in Capital Conversion Of Convertible Note And Derivative	Subscription Receivable	Accumulated Deficit	Accumulated Other Comprehensive Income
Beginning balances (in shares) at Dec. 31, 2023			24,508,795
Beginning balances at Dec. 31, 2023	$ (4,033)		$ 2		$ 64,468		$ (170)	$ (68,334)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants/Conversion of convertible note and derivative liability into common stock (in shares)			125,000
Exercise of warrants/Conversion of convertible note and derivative liability into common stock	6				6
Interest on recourse loan	4						4
Stock-based compensation	4,255				4,255
Net loss	(9,038)							(9,038)
Ending balances (in shares) at Mar. 31, 2024			24,633,795
Ending balances at Mar. 31, 2024	(8,806)		$ 2		68,729		(166)	(77,372)	0
Beginning balances (in shares) at Dec. 31, 2023			24,508,795
Beginning balances at Dec. 31, 2023	(4,033)		$ 2		64,468		(170)	(68,334)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(18,075)
Ending balances (in shares) at Jun. 30, 2024			36,529,574
Ending balances at Jun. 30, 2024	28,464		$ 4		114,870		0	(86,410)	0
Beginning balances (in shares) at Mar. 31, 2024			24,633,795
Beginning balances at Mar. 31, 2024	(8,806)		$ 2		68,729		(166)	(77,372)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of offering costs (in shares)			10,000,000
Issuance of common stock, net of offering costs	40,000		$ 1		39,999
Offering costs	(4,150)				(4,150)
Exercise of warrants/Conversion of convertible note and derivative liability into common stock (in shares)			18,341	2,104,562
Exercise of warrants/Conversion of convertible note and derivative liability into common stock		$ 6,803				$ 6,803
Exercise of options (in shares)			17,936
Exercise of options	9				9
Restricted Stock Awards Repurchased (in shares)			(245,060)
Interest and forgiveness on recourse loans	166						166
Stock-based compensation	3,480				3,480
Net loss	(9,038)							(9,038)
Ending balances (in shares) at Jun. 30, 2024			36,529,574
Ending balances at Jun. 30, 2024	28,464		$ 4		114,870		0	(86,410)	0
Beginning balances (in shares) at Dec. 31, 2024			51,288,566
Beginning balances at Dec. 31, 2024	131,681		$ 5		239,201		0	(107,525)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of offering costs (in shares)			4,210,525
Issuance of common stock, net of offering costs	75,847				75,847
Short-swing profit disgorgement	48				48
Vested restricted stock units (in shares)			121,660
Exercise of warrants/Conversion of convertible note and derivative liability into common stock (in shares)			1,164,644
Exercise of warrants/Conversion of convertible note and derivative liability into common stock	11,787				11,787
Exercise of options (in shares)			60,120
Exercise of options	138				138
Stock-based compensation	3,879				3,879
Net loss	(13,216)							(13,216)
Ending balances (in shares) at Mar. 31, 2025			56,845,515
Ending balances at Mar. 31, 2025	210,164		$ 6		330,900		0	(120,742)	0
Beginning balances (in shares) at Dec. 31, 2024			51,288,566
Beginning balances at Dec. 31, 2024	$ 131,681		$ 5		239,201		0	(107,525)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of options (in shares)	114,717
Net loss	$ (34,068)
Ending balances (in shares) at Jun. 30, 2025			59,333,332
Ending balances at Jun. 30, 2025	207,206		$ 6		348,494		0	(141,592)	298
Beginning balances (in shares) at Mar. 31, 2025			56,845,515
Beginning balances at Mar. 31, 2025	210,164		$ 6		330,900		0	(120,742)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of offering costs (in shares)			1,125,706
Issuance of common stock, net of offering costs	13,521				13,521
Vested restricted stock units (in shares)			216,685
Exercise of warrants/Conversion of convertible note and derivative liability into common stock (in shares)			1,092,542
Exercise of warrants/Conversion of convertible note and derivative liability into common stock	(411)				(411)
Exercise of options (in shares)			52,884
Exercise of options	86				86
Stock-based compensation	4,398				4,398
Other comprehensive income	298								298
Net loss	(20,850)							(20,850)
Ending balances (in shares) at Jun. 30, 2025			59,333,332
Ending balances at Jun. 30, 2025	$ 207,206		$ 6		$ 348,494		$ 0	$ (141,592)	$ 298